Skip to main content

Table 1 EGFRwt patients’ characteristics

From: Postoperative radiotherapy improves disease-free survival of EGFR wild-type pN2 non-squamous-cell non-small-cell lung cancer (Nsq-NSCLC) patients after complete resection: a propensity score matching analysis

 

Non-PORT

(n = 154)

PORT

(n = 90)

P value

Age

60 (50, 65)

57 (48, 62)

0.016

Sex

  

> 0.999

 Female

58 (37.7)

34 (37.8)

 

 Male

96 (62.3)

56 (62.2)

 

Smoking history

76 (49.4)

39 (43.3)

0.425

KPS

  

0.744

 > 80

124 (80.5)

71 (78.9)

 

 ≤ 80

30 (19.5)

19 (21.1)

 

Tumor location

  

0.227

 Left lung

70 (45.5)

33 (36.7)

 

 Right lung

84 (54.5)

57 (63,3)

 

cT

  

0.708

 1

50 (32.9)

30 (33.3)

 

 2

87 (57.2)

52 (57.8)

 

 3

14 (9.2)

6 (6.7)

 

 4

1 (0.7)

2 (2.2)

 

 Missing data

2

0

 

cN

  

0.032

 0

80 (52.3)

42(46.7)

 

 1

21 (13.7)

6 (6.7)

 

 2

48 (31.4)

42 (46.7)

 

 3

4 (2.6)

0 (0.0)

 

 Missing data

1

0

 

Cycles of chemotherapy

   

 < 4

21 (15.3)

5 (6.2)

0.114

 4

106 (77.4)

71 (87.7)

 

 > 4

10 (7.3)

5 (6.2)

 

 Missing data

17

9

 

pT

  

0.366

 1

29 (18.8)

23 (25.6)

 

 2

92 (59.7)

44 (48.9)

 

 3

30 (19.5)

20 (22.2)

 

 4

3 (1.9)

3 (3.3)

 

Positive lymph nodes

  

0.034

 ≤ 5

92 (59.7)

41 (45.6)

 

 > 5

62 (40.3)

49 (54.4)

 

Histology

61 (21.3)

22 (21.2)

0.303

 Adenocarcinoma

141 (91.6)

86 (95.6)

 

 Others a

13 (8.4)

4 (4.4)

 

Surgery type

  

0.799

 Open

76 (49.4)

43 (47.8)

 

 Thoracoscopic

78 (50.6)

47 (52.2)

 
  1. Data are median (IQR) or n (%) unless otherwise specified. a, including adenosquamous carcinoma, large cell carcinoma and other rare histology types. IQR, interquartile range; KPS, Karnofsky performance status; cT, clinical T stage; cN, clinical N stage; pT, pathological T stage